Joel Wertheimer
Psychiatry · Miami, FLNPI 1962477166
Payments from drug & device makers
Across 153 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$862
- Otsuka America Pharmaceutical, Inc.$494
- Johnson & Johnson$394
- Almatica Pharma LLC$306
- Alkermes, Inc.$219
- Lundbeck LLC$211
- plus $1K from 13 others
What the payments were for
- Food & beverage$3,577100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $862 |
| Otsuka America Pharmaceutical, Inc. | 25 | $494 |
| Johnson & Johnson | 15 | $394 |
| Almatica Pharma LLC | 14 | $306 |
| Alkermes, Inc. | 10 | $219 |
| Lundbeck LLC | 8 | $211 |
| Bausch Health US, LLC | 9 | $187 |
| Vanda Pharmaceuticals Inc. | 6 | $155 |
| AbbVie | 6 | $152 |
| Teva Pharmaceuticals USA, Inc. | 5 | $149 |
| E.r. Squibb & Sons, L.L.C. | 2 | $144 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Tris Pharma Inc | 3 | $70 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Corium, LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| TMS Neurohealth Centers Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,577 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 24 | $503 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $378 |
| Bupropion XlBupropion Hcl | 17 | $340 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 31 | $315 |
| Fluoxetine Hcl | 24 | $258 |
| Bupropion Hcl SrBupropion Hcl | 13 | $214 |
| Alprazolam | 20 | $208 |
| Trazodone Hcl | 21 | $179 |
| Duloxetine Hcl | 16 | $162 |
| Sertraline Hcl | 26 | $161 |
| Escitalopram Oxalate | 20 | $142 |
| Clonazepam | 15 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $306 | $16126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.